Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme

Ceftolozane-tazobactam is a combination of an antipseudomonal cephalosporin and a β-lactamase inhibitor. Ceftolozane-tazobactam was approved by the US Food and Drug Administration in 2014 and by the European Medicines Agency in 2015 for use in adults to treat complicated urinary tract infections, acute pyelonephritis, and complicated intra-abdominal infections with metronidazole. Studies for paediatric indications are planned. The Programme to Assess Ceftolozane-Tazobactam Susceptibility monitors the resistance of ceftolozane-tazobactam to Gram-negative isolates worldwide. In total, 6240 Gram-negative isolates were collected between 2012 and 2016 from paediatric patients (